Trial
NCT03935347
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
Iovance Biotherapeutics, Inc.
Condition
Metastatic Bladder Urothelial Carcinoma
Intervention
Cyclophosphamide
Why stopped
no accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-02